Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−81.7x

Market Cap

$12.20B

MomentumView details →

1D Return

−0.17%

YTD Return

+27.12%

RSI (14)

47.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−81.7x

Market Cap

$12.20B

RSI (14)

47.2

MomentumView details →

1D Return

−0.17%

YTD Return

+27.12%

SummaryUpdated Jun 1, 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a clinical-stage biotechnology company founded in 1989 and headquartered in Pasadena, California. The company went public in 1993 and has evolved into a leading developer of RNA interference (RNAi) therapeutics for treating rare and complex diseases. Arrowhead has built a proprietary platform technology that enables targeted delivery of RNAi medicines to specific tissues and organs, with a robust pipeline spanning multiple therapeutic areas including cardiometabolic diseases, pulmonary disorders, muscular dystrophy, and central nervous system conditions.

Ask drillr about Arrowhead Pharmaceuticals, Inc. →

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−47.79%

EBITDA Margin

−20.96%

ROE (TTM)

−68.73%

ROA (TTM)

−15.15%

Asset Turnover

0.31x

GrowthView details →

Revenue YoY

+12.22%

EPS YoY

−76.38%

FCF YoY

—

Revenue CAGR 3Y

+50.52%

EPS CAGR 3Y

+99.76%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$1.36

EPS Surprise

−6.25%

Beats (12Q)

2/12

Next Q EPS Est

−$1.59

Avg Surprise (4Q)

−27.43%

Rev Surprise

70.36%

Capital & dividendView details →

Debt/Equity

1.86x

Current Ratio

5.90x

Quick Ratio

5.90x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

669.50M

Net Income (TTM)

−319.95M

Op. CF (TTM)

−59.05M

Next earningsNov 24, 2026 →

Latest newsMore news →

Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026 in Munich, showing reduced acute pancreatitis events in patients with severe hypertriglyceridemia.5d ago

Arrowhead Pharmaceuticals announced it will present new clinical data for plozasiran at the European Society of Cardiology Congress in Munich, Germany, on August 30, 2026.12d ago

Similar companies

Corcept Therapeutics IncorporatedCORT Jiangsu Zenergy Battery Technologies Group Co., Ltd.03677.HK Ascentage Pharma Group International06855.HK Madrigal Pharmaceuticals, Inc.MDGL Halozyme Therapeutics, Inc.HALO Duality Biotherapeutics, Inc.09606.HK Find similar companies →

Latest newsMore news →

Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026 in Munich, showing reduced acute pancreatitis events in patients with severe hypertriglyceridemia.5d ago Arrowhead Pharmaceuticals announced it will present new clinical data for plozasiran at the European Society of Cardiology Congress in Munich, Germany, on August 30, 2026.12d ago Arrowhead Pharmaceuticals held its Q3 2026 earnings call on August 4, 2026.31d ago